Protein phosphatase 2A (PP2A) is a family of heterotrimeric protein phosphatases that has a multitude of functions inside the cell, acting through various substrate targets in cell-signaling pathways. Recent evidence suggests that a subset of PP2A holoenzymes function as tumor suppressors and one particular family of B subunits, B56, are implicated in this function. However, the regulatory mechanisms that govern activation of B56-PP2A tumor-suppressive function have not been elucidated. In the present study, we demonstrate that ataxiatelangiectasia mutated (ATM) directly phosphorylates and specifically regulates B56c3, B56c2 and B56d, after DNA damage. We further show that phosphorylation of B56c3 at Ser510 leads to an increase in B56c3-PP2A complexes, and direction of PP2A phosphatase activity toward the substrate p53, activating its tumor-suppressive functions. In addition, we found that under cell growth conditions B56c3 is kept at low levels through the actions of the E3 ubiquitin ligase MDM2, and, importantly, phosphorylation of B56c3 by ATM leads to upregulation of the protein by blocking MDM2-mediated B56c3 ubiquitination. Finally, we show that Ser510 phosphorylation significantly enhances the ability of B56c3 to inhibit cell proliferation and anchorage-independent growth. These results provide mechanistic insight into the regulation of PP2A tumor-suppressive function, and suggest a model for parallel regulation of p53 and B56c3.
Introduction
Protein phosphatase 2A (PP2A) is a family of serine/ threonine phosphoprotein phosphatases that acts in a multitude of cell-signaling pathways. Its multiple functions are thought to be regulated by dynamic exchange of regulatory (B) subunits that bind to the enzymatic core, consisting of a catalytic (C) subunit and a scaffolding (A) subunit (Sontag, 2001; Strack et al., 2002; Janssens et al., 2008; Virshup and Shenolikar, 2009) . The large number of B subunits can thereby direct the substrate specificity and subcellular localization of the heterotrimeric holoenzyme, conferring multiple distinct functions to the PP2A enzyme. Recently, PP2A was found to have tumor-suppressive functions inside the cell and one particular subset of B subunits is implicated in this function, namely the B56 (B 0 ) family (Mumby, 2007; Westermarck and Hahn, 2008; Eichorn et al., 2009) . To date, several PP2A substrate targets have been identified that are regulated in a manner consistent with PP2A functioning as a tumor suppressor. These include Cdc25c regulation by B56d-PP2A (PPP2R5D) as part of a DNA damage checkpoint pathway in Xenopus (Margolis et al., 2006) , B56a-PP2A (PPP2R5A) as a negative regulator of the myc oncogene (Yeh et al., 2004; Arnold and Sears, 2006) , and B56g-PP2A (PPP2R5C) as a positive regulator of the p53 tumor-suppressor protein after DNA damage (Li et al., 2007) .
The p53 protein is a very important tumor suppressor. Under cell-growth conditions p53 protein levels are kept low primarily by the action of the E3 ubiquitin ligase, MDM2, which targets p53 for degradation by the proteasome. After DNA damage, however, p53 becomes highly post-translationally modified, including several modifications that disrupt p53-MDM2 interaction, allowing for p53 upregulation and activation as a transcription factor. Once activated, p53 turns on the transcription of genes important for cell cycle arrest and apoptosis and thereby prevents the passage of damaged DNA onto further generations of cells. Work in our laboratory identified dephosphorylation of p53 at Thr55 by B56g-PP2A as an important event occurring after DNA damage, promoting p53 activation (Li et al., 2007) . Interestingly, phosphorylation of p53 at Ser15 by the DNA damage-sensing protein Ataxia-Telangiectasia Mutated (ATM) has been shown to prime the p53 molecule for enhanced interaction with B56g-PP2A and downstream Thr55 dephosphorylation and activation (Shouse et al., 2008) .
The link between ATM and the tumor-suppressor activity of B56g-PP2A is important in that it provides evidence for a pathway in which particular PP2A complexes can become activated in response to DNA damage in human cells. In fact, regulation of B subunits is one mechanism by which PP2A holoenzyme function can be regulated inside the cell. In this manner, either the level of particular B subunits or the affinity of B subunits for the PP2A core may be regulated temporally and spatially to alter the relative abundance of the corresponding PP2A complexes, thereby altering the overall functionality of the enzyme under different conditions. For example, B56d is a target for several important cellular kinases, including Chk1 (Margolis et al., 2006) and PKA (Ahn et al., 2007) . Phosphorylation of B56d by these kinases has been shown to affect PP2A phosphatase activity. To date, however, the precise mechanism by which B56-PP2A tumor-suppressive function is activated in response to DNA damage remains undefined.
In the present study, we demonstrate that upon DNA damage, the ATM protein kinase directly phosphorylates and specifically regulates three B subunits in the B56 family, B56g2, B56g3 and B56d. We further show that ATM-mediated Ser510 phosphorylation of B56g3 is a critical step in the upregulation of the protein and is required for the increase in abundance of B56g3-PP2A after DNA damage, suggesting that ATM phosphorylation may represent one of the mechanisms responsible for activating those B subunits of PP2A that are considered to have tumor-suppressive functions. We go further to demonstrate that, similar to p53, B56g3 ubiquitination is regulated by MDM2 under cell growth conditions and ATM-mediated Ser510 phosphorylation blocks MDM2 interaction and B56g3 ubiquitination. Interestingly, we also show that the ability of B56g3 to form a complex with p53 promotes efficient MDM2-mediated ubiquitination and downregulation of B56g3 under cell growth conditions, suggesting that the two tumor suppressors may be regulated in parallel as a complex. Finally, we demonstrate that Ser510 phosphorylation of B56g3 enhances p53 dephosphorylation and activation, as well as the p53-dependent tumorsuppressive function of B56g3-PP2A. Our results provide novel insight into a complex mechanism of specific regulation of a very important subset of PP2A B subunits and suggest a seemingly parallel mode of regulation of p53 and B56g3 activity.
Results

ATM directly phosphorylates B56g3 at Ser510 after DNA damage
We previously demonstrated that the protein levels of endogenous B56g3 and B56g2 increase after DNA damage (Li et al., 2007) . Based on the rapid induction of B56g3 and B56g2 protein levels, we tested whether protein stabilization may play a role in the process by using the proteasome inhibitor MG132 (Figure 1a) . The assay shows that treatment of MG132 led to an increased level of B56g protein even in the absence of DNA damage and the level remained constant after ionizing radiation (IR) treatment, suggesting that the ubiquitin-proteasome pathway may have a role in regulating B56g protein levels. Because B56g3 is associated with p53 in vivo (Li et al., 2007) and is stabilized after DNA damage in a manner similar to p53 (Figure 1a ), we reasoned that kinases known to target p53 might also target B56g3 after IR treatment. ATM is one of the major kinases that phosphorylate p53 at Ser15 rapidly after IR treatment. To test the requirement of ATM activity in B56g3 stabilization, we treated U2OS cells with the specific inhibitor of ATM kinase activity, KU55933 (Hickson et al., 2004) , and assayed for the effect on B56g3 and B56g2 upregulation after IR treatment. As shown in Figure 1a , blocking ATM kinase activity eliminated B56g upregulation after IR treatment, suggesting that the kinase activity of ATM may have a role in B56g protein level regulation. Interestingly, the protein levels of B56d, a B subunit that was previously reported to be phosphorylated by ATM (Nousiainen et al., 2006) , also increase after DNA damage. The protein levels of the other B subunits, as well as the C and A subunit of PP2A, however, remained unchanged under these conditions. Of note, the PP2A B56g gene encodes four differentially spliced forms, PP2A B56g1, g2, g3 and g4 (Muneer et al., 2002; Ortega-Lazaro and del Mazo, 2003) . Despite the fact that our antibody is able to detect B56g1 (Figure 5b ), endogenous B56g1 and g4 proteins were not detected.
To verify a specific role for the ATM kinase in regulating B56g and B56d upregulation after DNA damage, a pair of lymphoblast cell lines either containing or lacking ATM were subjected to IR (Figure 1b) . The normal cells showed induction of B56g3, B56g2 and B56d but not B56a protein, whereas the cells lacking ATM showed no induction, suggesting that ATM kinase activity is required for B56g and B56d upregulation after DNA damage.
Next, we investigated whether ATM could directly phosphorylate B56g and B56d in vivo using the ATM substrate phosphospecific antibody. As illustrated in Figure 1c , phosphorylation of endogenous B56g2, B56g3 and B56d was clearly detected, whereas phosphorylation of B56a under the same conditions was not. Importantly, IR treatment significantly increases the phosphorylation levels of B56g2, B56g3 and B56d, suggesting, upon DNA damage, that ATM specifically phosphorylates and upregulates only those B subunits. Analysis of the amino-acid sequences of these B subunits led to the identification of several potential ATM phosphorylation sites based on the consensus sequence surrounding known phospho-serine and phospho-threonine residues on other ATM-targeted proteins, including T399, S437 and S510 of B56g3 (Figure 1d and Supplementary Figure S1 ; Kim et al., 1999; O'Neill et al., 2000) .
In order to identify which residue of B56g is phosphorylated by ATM, several point mutants were generated, including T399A, S437A and S510A. These mutants were expressed in bacteria, purified and then subjected to an in vitro phosphorylation assay with purified ATM kinase. As shown in Figure 1e , although wild-type ATM was able to promote phosphorylation of wild-type B56g3, T399A and S437A, it was unable to phosphorylate the S510A mutant, suggesting that Ser510 may be the primary target for direct phosphorylation of B56g3 by ATM. In addition, B56g1 protein, which lacks the Ser510 residue (Figure 1d ), was also unable to be phosphorylated in vitro by ATM, providing additional evidence that Ser510 is the major ATM phosphorylation site on B56g3. No phosphorylation of wild-type B56g3 was detected in the presence of a kinase-dead ATM mutant (KD; Lim et al., 2000) , or in the presence of the ATM inhibitor. In addition, the S510A mutant was still able to interact with the PP2A core (Figures 2f and 4b) , suggesting that the mutation did not disrupt the conformation of the protein.
In order to verify that Ser510 was the major ATM phosphorylation site in vivo, U2OS cells were transfected with wild-type B56g3, B56g1 or the phosphorylation mutants, then subjected to IR (Figure 1f ). Phosphorylation of all of the B56g3 constructs except S510A was detected using the ATM substrate phosphospecific antibody at a low level under untreated conditions that dramatically increased after IR treatment, suggesting that Ser510 is the major residue of B56g3 targeted by ATM in vivo after DNA damage. Consistent with this finding, no phosphorylation was detected on B56g1.
In addition, we also show that B56d phosphorylation increased after IR treatment, whereas no phosphorylation was detected on the B56d phosphorylation mutant, S598A ( Figure 1f ; Nousiainen et al., 2006) .
ATM levels and activation of ATM kinase activity as detected by ATM autophosphorylation of Ser1981 suggest that ATM was activated under the assay conditions. Furthermore, addition of the ATM inhibitor KU55933 blocked ATM activation and the phosphorylation of the wild-type proteins. In support of this finding, we show that endogenous B56g and ATM interact in vivo and, importantly, this interaction is enhanced in response to IR treatment ( Figure 1g ). To firmly demonstrate a specific role for ATM in B56g3 Ser510 phosphorylation in vivo, lymphoblast cell lines either containing or lacking wild-type ATM were transfected with B56g3 or the S510A mutant, then subjected to IR treatment and assayed for ATM phosphorylation (Figure 1h ). The wild-type B56g3 protein was phosphorylated after DNA damage only in the presence of wild-type ATM, whereas the S510A mutant was not phosphorylated under any condition assayed, suggesting that ATM is specifically responsible for the phosphorylation detected on B56g3 protein after IR treatment. Further, overexpression of wild-type ATM, but not ATM KD, promoted phosphorylation of B56g3 protein in U2OS cells (Supplementary Figure  S2) . As a positive control, p53 Ser15 phosphorylation was also promoted by ATM overexpression.
Ser510 phosphorylation modulates B56g3 protein stability through regulation of MDM2-mediated protein degradation As we identified Ser510 as an ATM phosphorylation site and showed that ATM kinase activity is required for B56g3 upregulation after DNA damage, we investigated whether Ser510 phosphorylation directly affects B56g3 protein stability. As shown in Figure 2a and Supplementary Figure S3 , wild-type B56g3 half-life increases dramatically after DNA damage (from 4.9 to 11.2 h). Interestingly, the S510A mutant, which cannot be phosphorylated at Ser510, has a half-life (2.7 h) comparable to wild type under normal growth conditions, but is only slightly affected by DNA damage (3.4 h). In concordance with this finding, the phosphomimic mutant, S510D, shows a half-life under untreated conditions (11.7 h) similar to that of the wild-type protein under DNA damage conditions. After IR treatment, the S510D mutant has no further increase in stability (11.9 h). These results suggest that Ser510 phosphorylation is required in order to promote an increase in B56g3 protein stability after DNA damage.
As we demonstrated a seemingly parallel regulation mechanism of both p53 and B56g3 after DNA damage ( Figure 1a) and it was previously demonstrated that B56g3 is able to complex with the p53 E3 ubiquitin ligase, MDM2 (Okamoto et al., 2002) , we tested whether MDM2 affects B56g3 protein levels. As shown in Figure 2b , expression of MDM2, but not the RINGfinger mutant C464A, significantly decreased wild-type B56g3 and S510A protein levels, while S510D was unaffected. As a positive control, p53 levels were also downregulated by MDM2 under the same conditions.
To confirm this result, we show that MDM2 overexpression was sufficient to significantly decrease the half-life of both the wild-type and the S510A mutant B56g3 proteins, while it had no effect on the S510D mutant protein stability (Supplementary Figure S4) , suggesting that Ser510 phosphorylation blocks the MDM2-mediated downregulation of B56g3. To test the effect of MDM2 on endogenous B56g proteins, we assayed B56g protein levels in a cell line (SJSA-1) where MDM2 overexpression contributed to the cancerous phenotype (Figure 2h ). Clearly, endogenous MDM2 protein levels are much higher in this cell line and importantly, in addition to lower p53 protein levels, B56g3 and B56g2 protein levels are also much lower. Further, knockdown of MDM2 by RNAi in U2OS cells also leads to accumulation of B56g3 and B56g2 as well as p53 (Figure 2i) . The effects noted are most likely due to direct ubiquitination by MDM2, as the C464A mutant had no effect on any of the B56g3 protein constructs or p53 protein levels (Figure 2b and Supplementary Figure S4 ).
To test this directly, we sought to determine if MDM2 is able to promote the ubiquitination of B56g3. The assay shows that in the presence of overexpressed MDM2, but not C464A, the level of detectable B56g3 ubiquitination increased under both native ( Figure 2c ) and denaturing ( Figure 2d ) conditions, suggesting that MDM2 is able to ubiquitinate B56g3 protein. To test whether the MDM2-mediated ubiquitination of B56g3 was influenced by the Ser510 phosphostatus, we expressed the Ser510 phosphorylation mutants in U2OS cells and assayed their ubiquitination by either wild-type MDM2 or the C464A mutant (Figure 2e ). The assay shows that MDM2 was able to promote ubiquitination of both wild-type B56g3 and S510A but not S510D, suggesting that phosphorylation of B56g3 at Ser510 promotes B56g3 stabilization by blocking its ubiquitination by MDM2.
Next, we investigated whether Ser510 phosphorylation could also influence the interaction between B56g3 and MDM2. The assay showed that although the wild-type protein was able to interact with MDM2, the S510A mutant had a slightly higher interaction and the S510D mutant was unable to interact with MDM2 to any detectable level (Figure 2f ). To investigate whether B56g-MDM2 interaction is indeed affected under conditions where ATM kinase is activated, we treated cells with IR and showed that the interaction between endogenous B56g3, B56g2 and MDM2 decreased to almost undetectable levels (Figure 2g ). Together these results strongly suggest that Ser510 phosphorylation by ATM is able to disrupt B56g3-MDM2 interaction and B56g3 ubiquitination, providing insight into the potential mechanism underlying B56g3 upregulation after DNA damage.
Interaction with p53 promotes downregulation of B56g3 by MDM2 As p53 is associated with B56g3 and regulated by MDM2 in a manner similar to B56g3, we reasoned that it might have a role in B56g downregulation. Indeed when isogenic HCT116 cell lines either containing or lacking wild-type p53 protein were subjected to IR treatment (Figure 3a) , the B56g protein levels increased to a similar level in both cell lines; however, the amount of B56g3 without the treatment was much higher in the HCT116À/À cell line.
Next, we investigated the requirement of p53 for the B56g3-MDM2 interaction in either HCT116 p53 þ / þ or p53À/À cells. As shown in Figure 3b , the interaction between MDM2 and B56g protein was higher in the presence of p53, suggesting that the presence of p53 is not absolutely required for the interaction, but significantly promoted it. Consistent with this finding, overexpression of MDM2 but not the C464A mutant also led to a significant decrease in the levels of B56g3 protein and a significant increase in ubiquitinated B56g3 in the presence of p53, whereas in the absence of p53 the downregulation and ubiquitination were still present but to a lower degree (Figures 3c and d) .
Previously, we demonstrated that specific mutations within the p53-binding domain of B56g3, including Q392G/C398L (QC), could disrupt p53-B56g3 interaction (Shouse et al., 2010) . In order to further investigate the role of p53 interaction in mediating MDM2-B56g3 interaction, we tested whether this mutant could complex with MDM2 in vivo (Figure 3e ). As previously demonstrated, the QC mutant was unable to interact with p53 and, importantly, showed a decreased affinity for MDM2 as well. Consistent with this result, the QC mutant also showed a less significant downregulation by MDM2 (Figure 3f) . It has been previously described that B56g protein can interact with MDM2 in a complex that also includes cyclin G protein. To test whether cyclin G affects the B56g3-MDM2 interaction under our assay conditions, we tested whether cyclin G knockdown by RNAi could disrupt the B56g3-MDM2 interaction. As shown in Supplementary Figure S5 , knockdown of cyclin G had no detectable effect on the interaction between B56g and MDM2, suggesting that the interaction detected in our assay may be through a complex not dependent on the presence of cyclin G. In addition, knockdown of cyclin G also had no effect on the downregulation of B56g3 by MDM2 (Supplementary Figure S6) . Taken together, these results suggest that B56g3-p53 interaction has a role in bringing MDM2 to B56g3, which leads to downregulation of B56g3 under cell growth conditions.
Phosphorylation of B56g3 at Ser510 promotes Thr55 dephosphorylation and activation of p53 As B56g3 mediates p53 Thr55 dephosphorylation and activation, we tested whether the ATM phosphostatus of B56g3 could affect this function. Overexpression of wild-type B56g3 promoted p53 Thr55 dephosphorylation compared with the empty vector control, whereas the S510A mutant was unable to do so as efficiently (Figure 4a) . Interestingly, overexpression of the phosphomimic S510D mutant was able to promote Thr55 dephosphorylation more efficiently than even the wildtype protein. The expression levels of the p53 transcriptional target, p21, correlated well with the level of Thr55 dephosphorylation, such that p21 induction was highest for the S510D mutant and lowest for the S510A mutant. Taken together, the results indicate that phosphorylation of S510 promotes B56g3-mediated Thr55 dephosphorylation and activation of p53.
Next we investigated whether B56g3 Ser510 phosphorylation could directly influence its interaction with p53 in response to DNA damage. As shown in Figure 4b , although wild-type B56g3-p53 interaction increased after DNA damage, the S510A mutant had a weaker interaction with p53 under mock and IR conditions. The increased interaction seen between p53 and the S510A mutant can most likely be attributed to DNA-damage-induced modifications occurring on p53 previously shown to promote p53-B56g3 interaction, specifically Ser15 phosphorylation (Shouse et al., 2008) . The S510D mutant, on the other hand, had a stronger interaction with p53 under mock conditions and the interaction increased further after IR treatment. The greater interaction under mock conditions most likely represents the effect of Ser510 phosphorylation on p53-B56g3 interaction, whereas the further increase in interaction after DNA damage is most likely due to p53 modifications that further enhance the interaction. The fact that both the Ser510 phosphomimic mutant and wild-type B56g3 have similar levels of p53 interaction after DNA damage suggests that the maximum level of phosphorylation of B56g3 is attained after DNA damage and therefore a maximum level of p53 interaction is attained. Thus, in addition to stabilizing B56g3, Ser510 phosphorylation also has a significant role in promoting interaction with p53 after DNA damage. All three B56g3 constructs interacted with the PP2A core similarly and that interaction did not change after DNA damage, suggesting that Ser510 phosphorylation may specifically promote increased substrate interaction.
To confirm this result, U2OS cells transfected with wild-type B56g3 or the Ser510 phosphorylation mutants were also precipitated with microcystin beads that pull down the PP2A C subunit (Figure 4c ). All three B56g3 constructs interacted with the PP2A C subunit to similar levels, supporting the notion that the phosphorylation does not directly affect B56g3-PP2A complex formation. Interestingly, S510A mutant B56g3 was unable to promote as significant an interaction between the PP2A C subunit and p53 as was wild type, suggesting that B56g3 Ser510 phosphorylation can promote PP2A-p53 interaction. In addition, the S510D mutant led to a more enhanced PP2A-p53 interaction, in further support of this notion.
To verify the role of ATM in the interaction between B56g3-PP2A and p53, U2OS cells were either control treated or treated with the specific ATM inhibitor KU55933, then treated with IR. As shown in Figure 4d , in the control condition, endogenous B56g-PP2A complexes increase significantly after DNA damage in a manner that correlates with the upregulation of B56g protein levels and the dissociation of MDM2. Inhibition of the kinase activity of ATM, on the other hand, blocked both the upregulation of B56g protein levels and the B56g-PP2A complex. Interestingly, B56g-p53 interaction increased significantly in the control experiment, but addition of the ATM inhibitor blocked this enhanced interaction as well. These findings suggest that ATM kinase activity has a critical role in bridging B56g3-PP2A to p53, through phosphorylation of p53 at Ser15 as previously described (Shouse et al., 2008) and through phosphorylation of endogenous B56g at Ser510 in response to DNA damage.
Ser510 phosphorylation modulates B56g3 tumor-suppressive function
As we were able to demonstrate a role for B56g3 Ser510 phosphorylation in modulating p53 transcriptional activation (Figure 4a ), we wanted to investigate whether this phosphorylation influences p53-dependent tumorsuppressive functions of B56g3-PP2A. HCT116 cells expressing wild-type p53 were transfected with wild-type B56g3, S510A, S510D or B56g1. As shown in Figures 5a and c, the phosphomimic mutant S510D decreased cell proliferation more substantially than wild type, whereas the phospho-defect mutant S510A less than wild type. Consistent with the cell proliferation data, cells transfected with S510D showed increased levels of endogenous p21 expression than those transfected with wild-type B56g3, whereas cells transfected with S510A showed decreased levels of endogenous p21 expression than those transfected with wild-type B56g3 (Figure 5b) . These results suggest that phosphorylation of B56g3 at Ser510 is an important modification that enhances B56g3 tumor-suppressive function. In addition, the B56g1 isoform that lacks Ser510 residue was also able to only decrease cell proliferation and p21 expression to a similar degree as the S510A mutant, further supporting the importance of Ser510 phosphorylation in B56g3 tumor-suppressive function.
To investigate whether B56g3 affects cell G1 arrest, we performed FACS analysis (Figure 5f ). The assay showed that the B56g phospho-mimic mutant S510D induces cell G1 arrest more substantially than wild-type B56g (79 vs 72%), whereas the B56g phospho-defective mutant S510A induces it less than wild-type B56g (65 vs 72%). This result further supports our notion that ATM-mediated phosphorylation activates the tumorsuppressive function of B56g-PP2A.
As one indicator of tumorigenesis is the ability of cells to proliferate independently of attachment, we assayed the ability of Ser510 phosphorylation to influence B56g3 ability to block anchorage-independent cell growth. The number of colonies observed in the presence of the Ser510 phosphomimic mutant S510D was much lower than the number seen in the wild-type B56g3-transfected cells (Figures 5d and e) . On the other hand, the phospho-defect mutant, S510A, was unable to block colony formation as effectively as the wild-type protein.
As an additional control, B56g1 expression led to changes in colony number similar to S510A, whereas S437A mutant B56g3 showed effects similar to wild-type B56g3. Taken together, this evidence demonstrates the importance of Ser510 phosphorylation in modulating the tumor-suppressive functions of B56g3-PP2A.
Discussion
Although PP2A is considered as a single enzyme, it actually represents a family of specifically modulated enzymes that regulate many different pathways including cell growth, metabolism, development, regulation of the cell cycle and cell-stress response (Sontag, 2001; Strack et al., 2002; Janssens et al., 2008; Virshup and Shenolikar, 2009 ). In order for PP2A to function in these variable and sometimes opposing pathways, its activity must be specifically regulated. However, the precise regulatory mechanisms that control each specific PP2A activity under each individual physiological and pathological condition are still poorly understood. Furthermore, several studies point to the B56 family of PP2A B-subunits as the potential key required to influence the PP2A holoenzyme to act as a tumor suppressor (Mumby, 2007; Westermarck and Hahn, 2008; Eichorn et al., 2009) . Despite this knowledge, the upstream signals that link the actual DNA damage event to PP2A activation in human cells have not been clearly deciphered. We demonstrate that the DNA damage-sensing protein ATM is able to phosphorylate endogenous B56g3, B56g2 and B56d protein, and this phosphorylation is required for upregulation of these B subunits after DNA damage. Interestingly, other B56 family members tested were neither phosphorylated by ATM nor upregulated by DNA damage (Figures 1a-c) . These findings suggest that ATM may be specifically responsible for promoting upregulation of the subset of PP2A B subunits that confer its tumor-suppressive functions after DNA damage. It is worthwhile to mention that a mechanism for activation of B56d-PP2A in a DNA damage checkpoint has been previously described in Xenopus (Margolis et al., 2006) , in which B56d is phosphorylated by Chk1. Thus, it is possible that more than one DNA damage response kinase may be involved in the regulation of PP2A tumor-suppressive function.
Our data suggest that phosphorylation of B56g3 has two significant effects that influence PP2A tumorsuppressive function. First, the upregulation of B56g3 after ATM-mediated phosphorylation increases the abundance of B56g3-specific PP2A complexes, thereby potentially altering the function of PP2A inside the cell by altering the substrate target of the protein complex. Second, this phosphorylation also significantly enhances the interaction of the B56g3-PP2A complex with its substrate, p53, after DNA damage. This is in contrast to a previous report that phosphorylation of B56d by Chk1 in Xenopus was only able to enhance the interaction of B56d with the PP2A core (Margolis et al., 2006) . Thus, the mechanism we have uncovered may allow B56g3-PP2A to more specifically respond to DNA-damage signal and more effectively function as a tumor suppressor in human cells. Indeed, the significance of our findings is further enhanced by our demonstration of the influence of B56g3 Ser510 phosphorylation on p53 activation and PP2A tumor-suppressive function. Simulation of loss of Ser510 phosphorylation, using the S510A mutant, clearly inhibited the ability of B56g3 to efficiently promote dephosphorylation of p53 at Thr55 and induce p53 transcriptional activation as evidenced by p21 protein levels, whereas the S510D mutant significantly enhanced it (Figure 4a ). This trend was also clearly demonstrated in cell proliferation and anchorage-independent growth ( Figure 5 ). Together, these findings clearly demonstrate that phosphorylation of B56g3 by ATM can effectively influence PP2A tumorsuppressive function inside human cells.
In addition to demonstrating a function of B56g3 phosphorylation in mediating B56g3-PP2A tumor suppression, we go further to demonstrate the molecular mechanism by which B56g3 protein levels are dynamically controlled. Specifically, we show that B56g3-PP2A activity is downregulated under cell growth conditions by MDM2-mediated ubiquitination of B56g3 and stabilized and activated by a cascade of events promoted by ATMmediated phosphorylation of B56g3 subunits on Ser510 after DNA damage. Previous studies have suggested a possible role for the regulation of protein stability in regulation of PP2A B subunits (Silverstein et al., 2002) ; however, this is the first time that an E3 ligase has been elucidated that is capable of promoting ubiquitination of a PP2A B subunit. Our finding suggests that the ubiquitin proteasome pathway may represent an important control mechanism for keeping PP2A tumor-suppressive activity off to allow for cell growth. In the future, it will be interesting to find whether other PP2A B subunits are regulated in a similar manner, or even whether they are also regulated by MDM2.
Finally, it is tempting to speculate a parallel regulation model for p53 and B56g3 proteins. First, phosphorylation of both proteins by ATM, p53 at Ser15 and B56g3 at Ser510, is important for activation of both proteins after DNA damage. Both Ser15 and Ser510 phosphorylations have been shown to enhance B56g3-PP2A-p53 interaction and PP2A tumor-suppressive functions. This regulatory mechanism may be required to ensure efficient transduction of the DNA-damage signal from ATM to the effector proteins that regulate the cell cycle to allow for repair of damage DNA. Another parallel regulation of p53 and B56g3 is ubiquitination by MDM2. Interestingly, in the absence of p53, the ubiquitination of B56g3 and the B56g3-MDM2 interaction are both decreased. This finding suggests a coordinated downregulation of p53 and B56g3 under cell-growth conditions. By binding and downregulating both p53 and a protein responsible for activation of p53, B56g3, MDM2 can thus more effectively keep p53 activity in check. Further study of this parallel regulation model may lead to new understanding of p53 regulation.
Materials and methods
Cell culture, plasmids and RNA interference U2OS cells and HCT116 cells were cultured in McCoy's 5A medium supplemented with 10% fetal calf serum. GM02254 and GM01526 lymphoblasts were cultured in RPMI 1640 medium supplemented with 15% fetal calf serum. SJSA-1 cells were cultured in RPMI 1640 medium supplemented with 10% fetal calf serum. To induce DNA damage, the cells were subjected to gamma radiation (6 Gy for U2OS and 8 Gy for GM). In ATM inhibition experiments, cells were treated with 10 mM KU55933 (a gift from Dr G Smith) or dimethyl sulfoxide control as indicated. The Flag-ATM and Flag-ATM-KD plasmids were gifts from Dr M Kastan. The B56g3 mutants T399A, S437A, S510A and S510D were generated by using a QuikChange sitedirected mutagenesis kit (Stratagene, La Jolla, CA, USA). All plasmids were verified by sequencing. For cyclin G knock down, siGENOME SMARTpool cyclin G-siRNA (Dharmacon, Lafayette, CO, USA) was introduced into cells by using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA).
Western blot, immunoprecipitation and ubiquitination Whole-cell extract was prepared by lysing the cells in a buffer containing 50 mM Tris-HCl (pH 8.0), 120 mM NaCl, 0.5% NP-40, 1 mM DTT, 2 mg/ml aprotinin and 2 mg/ml leupeptin. Cell lysates were subjected to SDS-polyacrylamide gel electrophoresis (PAGE), followed by immunoblotting analysis with anti-p53 (DO1, Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-p21 (C-19, Santa Cruz Biotechnology), anti-PP2A A subunit (Upstate), anti-PP2A C subunit (1D6, Upstate, Lake Placid, NY, USA), anti-PP2A B56g3 (Shouse et al., 2008) , anti-ATM phospho Ser1981 (MAB3806, Chemicon, Billerica, MA, USA), anti-ATM (2C1, Genetex, Irvine, CA, USA), anti-p53 phospho Ser15 (Cell Signaling Technology, Danvers, MA, USA), anti-Cyclin G (Santa Cruz Biotechnology), anti-MDM2 (N-20, Santa Cruz Biotechnology), anti-PP2A B56a (Santa Cruz Biotechnology), anti-PP2A B56b (Santa Cruz Biotechnology), anti-PP2A B56d (a gift from Dr D Virshup), anti-PP2A B55a (Upstate), anti-HA (12CA5), anti-vinculin (VIN-11-5, Sigma) or anti-myc (9B11, Cell Signaling Technology) antibodies. For Thr55 dephosphorylation, the cell lysate was immunoprecipitated with phosphospecific antibody for Thr55 (Ab202; Li et al., 2007) and immunoblotted with anti-p53 antibody. For interaction of p53 or MDM2 with B56 proteins, U2OS cells were transfected with various B56 plasmids using FuGene (Roche, Nutley, NJ, USA) and lysed 28 h after transfection. Immunoprecipitation was performed using anti-HA monoclonal antibody or antiB56g antibody. The amounts of co-precipitated proteins were determined by immunoblotting. For microcystin binding assay, U2OS cell lysate was incubated with microcystin agarose beads (Upstate). For native ubiquitination assay, myc-ubiquitin or an empty vector control was co-transfected with MDM2 or an empty vector control along with one of the HA-B56g plasmids into U2OS cells using FuGene (Roche). After 36 h, cells were lysed and subjected to immunoprecipitation with anti-myc (Ab910B, Abcam, Cambridge, MA, USA) antibody, followed by immunoblotting with anti-HA antibody. For denature ubiquitination assay, His-ubiquitin or an empty vector control was co-transfected with MDM2 or an empty vector control along with one of the HA-B56g plasmids into U2OS cells using FuGene (Roche). After 36 h, cells were lysed and subjected to precipitation with nickel beads under denaturing conditions, followed by immunoblotting with anti-HA antibody. Cells were pre-treated with the proteasome inhibitor MG132 to normalize endogenous B56g protein levels in all ubiquitination experiments.
Phosphorylation of B56 subunits by ATM For in vitro ATM phosphorylation experiments, GST-B56g fusion proteins were expressed in BL21 bacteria and purified using glutathione sepharose beads. Purified B56g proteins were eluted after treatment with PreScision Protease (GE Healthcare Life Sciences, Pittsburgh, PA, USA). FLAG-ATM constructs were expressed in 293T cells and purified as previously described (Canman et al., 1998 ). Purified ATM protein was then incubated with the purified B56g protein in the presence of 32 P-ATP and the kinase reactions were carried out as previously described (Canman et al., 1998) . Proteins were then analyzed by SDS-PAGE followed by immunoblotting or autoradiography. For in vivo ATM phosphorylation experiments, cells were pre-treated with the proteasome inhibitor MG132 to normalize the B56g protein levels and the cell lysate was immunoprecipitated with anti-HA, anti-B56g or anti-B56d antibodies and immunoblotted with anti-ATM substrate phosphorylation antibody (Cell Signaling Technology).
Cell proliferation and anchorage-independent growth assays To generate proliferation curves, HCT116 cells were transfected with wild type, S510A or S510D mutant B56g3, or a control CMV empty vector using FuGene (Roche), seeded in triplicate and counted at 0, 24, 48, 72, 96 and 120 h post seeding.
For anchorage-independent growth assays, HCT116 cells were transfected with wild type, S510A or S510D mutant B56g3, or a control CMV empty vector seeded in triplicate in 0.35% Noble Agar (Fisher, Waltham, MA, USA) and counted 4 weeks post seeding.
Cell cycle profile analysis U2OS cells were transfected with empty vector or B56g3 plasmids, together with a green fluorescent protein expression vector. Cells were harvested 60 h after transfection, fixed in 0.4% paraformaldehyde, and stained with 50 mg/ml propidium iodide. Cell cycle phase distributions of green fluorescent proteinpositive cells were determined by FACScan flow cytometry (Becton Dickson, Franklin Lakes, NJ, USA).
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